Remicade does well in study on inflammation

Article

Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.

Related Videos
Related Content

Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD

October 1st 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD

October 1st 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD

October 1st 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023
© 2023 MJH Life Sciences

All rights reserved.